Greggs acknowledged that the rising popularity of weight loss drugs is impacting its financial performance, as consumers shift towards smaller portions and healthier options. The bakery chain's CEO, Roisin Currie, stated that there was "no doubt" appetite-suppressing drugs were influencing customer choices, contributing to the company's "lacklustre profits" and a "muted forecast" for the coming year.

While specific figures weren't disclosed regarding the direct impact of these drugs on Greggs' revenue, Currie highlighted a broader health trend with increased demand for protein and fibre. This shift has prompted Greggs to adapt its product offerings, moving away from its traditional high-fat pastries and cakes. In July, the company announced plans to target customers using weight loss drugs by introducing smaller portions and protein-rich products, exemplified by the launch of its egg-pot alongside the "eggs at Greggs" advertising campaign.

The market for weight loss drugs, particularly GLP-1 receptor agonists, has experienced significant growth, impacting the food and beverage industry. Several firms have reported changing consumer appetites as a result. This trend presents both a challenge and an opportunity for companies like Greggs, forcing them to innovate and cater to evolving dietary preferences.

Greggs, a British bakery chain, has historically focused on providing affordable and convenient food options. The company's response to the changing market reflects a strategic effort to maintain relevance and competitiveness. By introducing healthier alternatives and smaller portion sizes, Greggs aims to retain customers who are increasingly conscious of their health and weight.

Looking ahead, Greggs will likely continue to adapt its product portfolio to align with evolving consumer demands. The company's success will depend on its ability to effectively balance its traditional offerings with healthier options, while navigating the broader market trends influenced by weight loss drugs and changing dietary habits.